Neuland Laboratories

Neuland Laboratories P/TBV

The Price to Tangible Book Value (P/TBV) of Neuland Laboratories (NEULANDLAB.NS) as of Nov 19, 2026 is 9.98. In the previous year, Price to Tangible Book Value (P/TBV) was 12.83 — a change of -22.23% (lower).

P/TBV

9.98

YoY

-22.23%

Last updated:

Price to Tangible Book Value (P/TBV) of Neuland Laboratories is 2026 9.98 . Price to Tangible Book Value (P/TBV) of Neuland Laboratories was 2025 12.83 . It decreases by -22.23% lower compared to the previous year.

The Neuland Laboratories P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2019
38.08 INR
Jan 1, 2020
37.15 INR
Jan 1, 2021
31.62 INR
Jan 1, 2022
28.48 INR
Jan 1, 2023
22.32 INR
Jan 1, 2024
15.91 INR
Jan 1, 2025
12.83 INR
Jan 1, 2026
9.98 INR
The Neuland Laboratories P/TBV history
YEARP/TBVYoY
9.98-22.23%
12.83-19.32%
15.91-28.72%
22.32-21.65%
28.48-9.92%
31.62-14.90%
37.15-2.44%
38.08-33.79%
57.51-4.31%
60.10-135.24%
-170.57-272.06%
99.13-23.16%
129.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Price to Tangible Book Value (P/TBV) of Neuland Laboratories is 9.98 in 2026.

Price to Tangible Book Value (P/TBV) of Neuland Laboratories changed from 12.83 to 9.98, representing a -22.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Neuland Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neuland Laboratories

All Key Metrics — Neuland Laboratories